Skip to main content
SpringerLink
Log in

Psychopharmacology and Women

  • Chapter
  • First Online:
Women's Mental Health

Abstract

Psychopharmacological treatment has been one of the main therapeutic alternatives in psychiatry in the last five decades. However, some issues regarding the peculiarities of the populations being treated have been neglected throughout this history. Women represent the majority of patients with psychiatric diagnoses and also predominate among users of psychoactive drugs. However, since the preclinical development of the drugs, there has been a trend toward standardization of drug indications and doses, which clearly does not consider the differences between sexes. The complexity of women’s hormonal physiology translates into mood instability related to the menstrual cycle, the extremely complex physiological changes of pregnancy, and, finally, menopause. The purpose of this chapter is to review the peculiarities of psychopharmacological treatment in women. In order to achieve this objective, the following structure was adopted: section “Introduction” is meant to provide a brief introduction to the topic, section “Pharmacodynamics and Women” to cover pharmacodynamics and address gender differences regarding the mechanisms of action, and section “Pharmacokinetics and Women” to discuss pharmacokinetics and to review peculiarities in terms of absorption, distribution, metabolization, and excretion. In section “Specific Groups of Drugs and Gender Differences in Psychopharmacology,” we discuss specific issues about the main classes of psychotropic drugs in nonpregnant women in the period between puberty and menopause, and in section “Psychopharmacological Issues in Pregnancy and Breastfeeding,” we address psychopharmacological treatment in pregnancy and breastfeeding. Finally, in section “Conclusion,” we have the chapter completion, summarizing the relevance of the previously described issues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fankhauser MP. Psychiatric disorders in women: psychopharmacologic treatments. J Am Pharm Assoc (Wash). 1997;NS37(6):667–78.

    Article  CAS  Google Scholar 

  2. Clayton AH. Gender differences in clinical psychopharmacology. J Clin Psychiatry. 2005;66(9):1191.

    Article  PubMed  Google Scholar 

  3. Marazziti D, Baroni S, Picchetti M, Piccinni A, Carlini M, Vatteroni E, Falaschi V, Lombardi A, Dell’Osso L. Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. CNS Spectr. 2013;18(3):118–27.

    Article  PubMed  Google Scholar 

  4. Franconi F, Campesi I. Sex impact on biomarkers, pharmacokinetics and pharmacodynamics. Curr Med Chem. 2017;24:2561–75.

    Article  CAS  PubMed  Google Scholar 

  5. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, Ceconi C, Drexel H, Kjeldsen K, Savarese G, Torp-Pedersen C, Atar D, Lewis BS, Agewall S. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3(3):163–82.

    Article  CAS  PubMed  Google Scholar 

  6. Bolea-Alamanac B, Bailey SJ, Lovick TA, Scheele D, Valentino R. Female psychopharmacology matters! Towards a sex-specific psychopharmacology. J Psychopharmacol. 2018;32(2):125–33.

    Article  CAS  PubMed  Google Scholar 

  7. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 2000;25(3):197–220.

    Article  CAS  PubMed  Google Scholar 

  8. Buretić-Tomljanović A. Pharmacogenomics of mental illnesses: do sex-specific differences matter? Psychiatr Danub. 2007;19(3):222–30.

    PubMed  Google Scholar 

  9. Islam MM, Iqbal U, Walther BA, Nguyen PA, Li YJ, Dubey NK, Poly TN, Masud JHB, Atique S, Syed-Abdul S. Gender-based personalized pharmacotherapy: a systematic review. Arch Gynecol Obstet. 2017;295(6):1305–17.

    Article  PubMed  Google Scholar 

  10. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry. 1992;149(5):587–95.

    Article  CAS  PubMed  Google Scholar 

  11. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50(2):222–39.

    Article  CAS  PubMed  Google Scholar 

  12. Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry. 2017;4(2):146–58.

    Article  PubMed  Google Scholar 

  13. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003;28(Suppl 3):1–23.

    CAS  PubMed  Google Scholar 

  14. Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology. 2003;28(Suppl 3):55–99.

    Article  CAS  PubMed  Google Scholar 

  15. Halbreich U, Backstrom T, Eriksson E, O’brien S, Calil H, Ceskova E, Dennerstein L, Douki S, Freeman E, Genazzani A, Heuser I, Kadri N, Rapkin A, Steiner M, Wittchen HU, Yonkers K. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol. 2007;23(3):123–30.

    Article  PubMed  Google Scholar 

  16. Li SH, Graham BM. Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones. Lancet Psychiatry. 2017;4:73–82.

    Article  PubMed  Google Scholar 

  17. McEwen BS, Milner TA. Understanding the broad influence of sex hormones and sex differences in the brain. J Neurosci Res. 2017;95:24–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Phillips SP, Hamberg K. Doubly blind: a systematic review of gender in randomised controlled trials. Glob Health Action. 2016;9:29597.

    Article  PubMed  Google Scholar 

  19. Bennett JC. Inclusion of women in clinical trials--policies for population subgroups. N Engl J Med. 1993;329(4):288–92.

    Article  CAS  PubMed  Google Scholar 

  20. Bigos KL, Pollock BG, Stankevich BA, Bies RR. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med. 2009;6(4):522–43.

    Article  PubMed  Google Scholar 

  21. Arnett MG, Muglia LM, Laryea G, Muglia LJ. Genetic approaches to hypothalamic-pituitary-adrenal axis regulation. Neuropsychopharmacology. 2016;41(1):245–60.

    Article  CAS  PubMed  Google Scholar 

  22. Pigott TA. Gender differences in the epidemiology and treatment of anxiety disorders. J Clin Psychiatry. 1999;60(Suppl 18):4–15.

    PubMed  Google Scholar 

  23. Wise DD, Felker A, Stahl SM. Tailoring treatment of depression for women across the reproductive lifecycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology. CNS Spectr. 2008;13(8):647–62.

    Article  PubMed  Google Scholar 

  24. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499–523.

    Article  CAS  PubMed  Google Scholar 

  25. Usall i Rodié J. Gender based psychopharmacology: gender influence in the pharmacological treatment of mental disorders. Actas Esp Psiquiatr. 2004;32(5):307–13.

    PubMed  Google Scholar 

  26. Franconi F, Brunellesch S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55(2):81–95.

    Article  CAS  PubMed  Google Scholar 

  27. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014;171(3):580–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Franconi F, Campesi I. Sex and gender influences on pharmacological response: an overview. Expert Rev Clin Pharmacol. 2014;7(4):469–85.

    Article  CAS  PubMed  Google Scholar 

  30. Hashimoto S, Miwa M, Akasofu K, Nishida E. Changes in 40 serum proteins of post-menopausal women. Maturitas. 1991;13:23–33.

    Article  CAS  PubMed  Google Scholar 

  31. Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactant in postmenopausal women. Arterioscler Thromb Vasc Biol. 1997;17:1822–9.

    Article  CAS  PubMed  Google Scholar 

  32. Kishino S, Nomura A, Itoh S, et al. Age- and gender related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities. Eur J Clin Pharmacol. 2002;58:621–8.

    Article  CAS  PubMed  Google Scholar 

  33. Blain PG, Mucklow JC, Rawlins MD, et al. Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health. Br J Clin Pharmacol. 1985;20:500–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1996;21:123–8.

    Article  CAS  PubMed  Google Scholar 

  35. Wilson K. Sex-related differences in drug disposition in man. Clin Pharmacokinet. 1984;9:189–202.

    Article  CAS  PubMed  Google Scholar 

  36. Nazir S, Iqbal Z, Shah Y, Ahmad L, Khan A. Pharmacokinetic study of rosuvastatin in males and females. Eur J Drug Metab Pharmacokinet. 2015;40(3):313–8.

    Article  CAS  PubMed  Google Scholar 

  37. Nicolas JM, Espie P, Molimard M. Gender and interindividual variability in pharmacokinetics. Drug Metab Rev. 2009;41(3):408–21.

    Article  CAS  PubMed  Google Scholar 

  38. Hamilton J, Yonkers K. Sex differences in pharmacokinetics of psychotropic medication, part I: physiological basis for effects. In: Jensvold M, Halbreich U, Hamilton J, editors. Psychopharmacology and women: sex, gender, and hormones. Washington, DC: American Psychiatric Press; 1996. p. 11–42.

    Google Scholar 

  39. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol Bull. 1997;33:235–41.

    CAS  PubMed  Google Scholar 

  40. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62:400–7.

    Article  CAS  PubMed  Google Scholar 

  41. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007;82(1):87–96.

    Article  CAS  PubMed  Google Scholar 

  42. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive related gender differences. Eur J Clin Pharmacol. 1999;55:177–85.

    Article  CAS  PubMed  Google Scholar 

  43. Edeki T, Goldstein JA, de Morais SMF, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics. 1996;6:357–63.

    Article  CAS  PubMed  Google Scholar 

  44. Sviri S, Shpizen S, Leitersdorf E, Levy M, Caraco Y. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Ther. 1999;65:275–81.

    Article  CAS  PubMed  Google Scholar 

  45. Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001;51:169–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Anderson GD. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase. J Gend Specif Med. 2002;5:25–33.

    PubMed  Google Scholar 

  47. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N acetyltransferase, xanthine oxidase and CYP1A2 activities. Clin Pharmacol Ther. 1992;52:643–53.

    Article  CAS  PubMed  Google Scholar 

  48. Wrighton SA, Stevens JC. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22:1–12.

    Article  CAS  PubMed  Google Scholar 

  49. Bock K, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine and paracetamol as probes. Pharmacogenetics. 1994;4:209–19.

    Article  CAS  PubMed  Google Scholar 

  50. Jennings TS, Nafziger AN, Davidson L, et al. Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med. 1993;122:208–17.

    CAS  PubMed  Google Scholar 

  51. Nemeroff C, De Vane C, Pollock B. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311–20.

    Article  CAS  PubMed  Google Scholar 

  52. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107–21.

    Article  CAS  PubMed  Google Scholar 

  53. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994;16(5):513–8.

    Article  CAS  PubMed  Google Scholar 

  54. Jerling M, Merle Y, Mentre F, Mallet A. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1997;44:447–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Wolbrette D. Gender differences in the proarrhythmic potential of QT-prolonging drugs. Curr Womens Health Rep. 2002;2:105–9.

    PubMed  Google Scholar 

  56. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol. 1992;19:603–6.

    Article  CAS  PubMed  Google Scholar 

  57. Baptista T, Kin NM, Beaulieu S, De Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002;35:205–19.

    Article  CAS  PubMed  Google Scholar 

  58. Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology. 1989;96(1):11–7.

    Article  CAS  PubMed  Google Scholar 

  59. Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry. 1998;59(Suppl 2):18–28.

    PubMed  Google Scholar 

  60. Payne JL. Psychopharmacology in pregnancy and breastfeeding. Psychiatr Clin North Am. 2017;40(2):217–38.

    Article  PubMed  Google Scholar 

  61. Wisner KL, Zarin DA, Holmboe ES, Appelbaum PS, Gelenberg AJ, Leonard HL, Frank E. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry. 2000;157(12):1933–40.

    Article  CAS  PubMed  Google Scholar 

  62. Camacho RS, Cantinelli FS, Ribeiro CS, Cantilino A, Gonsales BK, Braguittoni E, Rennó R Jr. Psychiatry disorders in pregnancy and puerperium: classification, diagnosis and treatment. Rev Psiq Clín. 2006;33(2):92–102.

    Article  Google Scholar 

  63. McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, Green L, Gregoire A, Howard LM, Jones I, Khalifeh H, Lingford-Hughes A, McDonald E, Micali N, Pariante CM, Peters L, Roberts A, Smith NC, Taylor D, Wieck A, Yates LM, Young AH, endorsed by the British Association for Psychopharmacology. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519–52.

    Article  PubMed  Google Scholar 

  64. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633–9.

    Article  CAS  PubMed  Google Scholar 

  65. Koren G. Is it appropriate to study the pharmacokinetics of drugs aimed at pregnant women in men? J Obstet Gynaecol Can. 2010;32(7):629–32.

    Article  PubMed  Google Scholar 

  66. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214–20.

    Article  PubMed  Google Scholar 

  67. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother. 2004;38(7–8):1265–71.

    Article  CAS  PubMed  Google Scholar 

  68. Pearlstein T. Use of psychotropic medication during pregnancy and the postpartum period. Womens Health (Lond). 2013;9(6):605–15.

    Article  CAS  Google Scholar 

  69. Peng M, Gao K, Ding Y, et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology. 2013;228(4):577–84.

    Article  CAS  PubMed  Google Scholar 

  70. Haervig KB, Mortensen LH, Hansen AV, et al. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23(5):526–33.

    Article  CAS  PubMed  Google Scholar 

  71. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med. 2000;30(1):89–94.

    Article  CAS  PubMed  Google Scholar 

  72. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14(12):823–7.

    Article  CAS  PubMed  Google Scholar 

  73. O’Brien L, Einarson TR, Sarkar M, et al. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can. 2008;30(8):696–701.

    Article  PubMed  Google Scholar 

  74. Wang S, Yang L, Wang L, et al. Selective serotonin reuptake inhibitors (SSRIs) and the risk of congenital heart defects: a meta-analysis of prospective cohort studies. J Am Heart Assoc. 2015;4(5):e001681.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397–407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Huybrechts KF, Bateman BT, Palmsten K, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Kobayashi T, Matsuyama T, Takeuchi M, et al. Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: a systematic review and meta-analysis. Reprod Toxicol. 2016;65:170–8.

    Article  CAS  PubMed  Google Scholar 

  78. Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet. 1973;2(7824):318–9.

    Article  CAS  PubMed  Google Scholar 

  79. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372–83.

    Article  CAS  PubMed  Google Scholar 

  80. Moretti ME. Psychotropic drugs in lactation–Motherisk Update 2008. Can J Clin Pharmacol. 2009;16(1):e49–57.

    PubMed  Google Scholar 

  81. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology. 2005;64(6):955–60.

    Article  CAS  PubMed  Google Scholar 

  82. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271(2):146–50.

    Article  CAS  PubMed  Google Scholar 

  83. Westin AA, Brekke M, Molden E, Skogvoll E, Aadal M, Spigset O. Changes in drug disposition of lithium during pregnancy: a retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norway. BMJ Open. 2017;7(3):e015738.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. European College of Neuropsychopharmacology, Utrecht, The Netherlands

    Marcelo Allevato

  2. The American Psychiatric Association, Washington, DC, USA

    Marcelo Allevato & Juliana Bancovsky

Authors
  1. Marcelo Allevato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juliana Bancovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of São Paulo, São Paulo, Brazil

    Joel Rennó Jr.

  2. Women’s Mental Health Clinic, Incestuous Families Treatment Clinic of Clinica’s Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Gislene Valadares

  3. Federal University of Pernambuco, Recife, Pernambuco, Brazil

    Amaury Cantilino

  4. Brazilian Association of Psychiatry, Rio de Janeiro, Brazil

    Jeronimo Mendes-Ribeiro

  5. Private Practice, São Lucas Medical Institute Criciúma, Santa Catarina, Brazil

    Renan Rocha

  6. Brazilian Association of Psychiatry (ABP), Rio de Janeiro, Brazil

    Antonio Geraldo da Silva

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Allevato, M., Bancovsky, J. (2020). Psychopharmacology and Women. In: Rennó Jr., J., Valadares, G., Cantilino, A., Mendes-Ribeiro, J., Rocha, R., Geraldo da Silva, A. (eds) Women's Mental Health. Springer, Cham. https://doi.org/10.1007/978-3-030-29081-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-29081-8_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-29080-1

  • Online ISBN: 978-3-030-29081-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation